Protagonist Therapeutics (PTGX) Long-Term Investments (2016 - 2026)
Protagonist Therapeutics (PTGX) posted Long-Term Investments of $72.5 million for Q1 2026, down 7.7% sequentially from $78.6 million in Q4 2025, and down 41.26% YoY from $123.5 million in Q1 2025.
Protagonist Therapeutics (PTGX) Long-Term Investments (2016 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Long-Term Investments for 9 years, with the latest figure at $72.5 million in Q1 2026.
- Quarterly Long-Term Investments fell 41.26% year-over-year to $72.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.5 million (down 41.26% YoY) and the FY2025 annual result came in at $78.6 million, down 43.98% from the prior year.
- Long-Term Investments declined to $72.5 million in Q1 2026 per PTGX's latest filing, from $78.6 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $140.3 million in Q4 2024 and troughed at $2.0 million in Q3 2023.
- A 4-year average of $85.4 million and a median of $102.5 million in 2025 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments jumped 5673.3% in 2024, then plunged 43.98% in 2025.
- Over 4 years, Long-Term Investments stood at $2.0 million in 2023, then soared by 6968.01% to $140.3 million in 2024, then slumped by 43.98% to $78.6 million in 2025, then retreated by 7.7% to $72.5 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $72.5 million, $78.6 million, and $102.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 66.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.90 Mn |
| Mar 31, 2026 | 72.55 Mn |
| Dec 31, 2025 | 78.60 Mn |
| Sep 30, 2025 | 102.70 Mn |
| Jun 30, 2025 | 102.50 Mn |
| Mar 31, 2025 | 123.52 Mn |
| Dec 31, 2024 | 140.30 Mn |
| Sep 30, 2024 | 114.60 Mn |
| Jun 30, 2024 | 31.40 Mn |
| Sep 30, 2023 | 1.99 Mn |
| Sep 30, 2021 | 38.20 Mn |
| Jun 30, 2021 | 26.10 Mn |
| Mar 31, 2021 | 6.30 Mn |
| Dec 31, 2020 | 2.00 Mn |
| Sep 30, 2020 | 6.00 Mn |
| Mar 31, 2018 | 5.56 Mn |
| Dec 31, 2017 | 11.46 Mn |
| Sep 30, 2017 | 11.32 Mn |
| Mar 31, 2017 | 14.00 Mn |
| Dec 31, 2016 | 10.15 Mn |